How To List A Medicine On The ARTG As An AUST L: Sponsor Steps And Practical Checklist

AUST L Listed Medicine

ARTG listing pathway for eligible lower-risk medicines that meet listing requirements and carry an AUST L number.

This article walks through the practical steps a sponsor or supply‑chain partner should follow to place a lower‑risk product on the ARTG under the AUST L pathway. It focuses on sponsor responsibilities, the core documentation and practical controls that reduce compliance risk during listing and post‑market supply.

Initial Assessment And Eligibility

Begin with a compliance assessment of formulation, intended use and proposed claims. Confirm the product uses permitted active ingredients at acceptable concentrations and that its presentation is consistent with low‑risk, consumer self‑selection. If the product suggests treatment of serious conditions, systemic action or requires professional administration, listing is not the correct pathway.

Establish Sponsor And eBusiness Services Access

Only a registered sponsor can create an ARTG entry. Sponsors must have an account with the TGA’s eBusiness Services (eBS). Sponsors should set up internal roles for those who will submit listings and maintain the ARTG entry and ensure secure credentialing. If you are an overseas manufacturer, appoint an Australian sponsor or authorized representative who accepts ARTG responsibilities.

Prepare Required Information

Gather the product information required for the ARTG entry: ingredient list (active and excipients), recommended use and permitted indications, dosage form, batch and manufacturing details, and proposed labelling and packaging text. Sponsors should also compile evidence of compliance with manufacturing standards and any certificates of analysis or GMP documentation they will rely on during supply or audit.

• Product Data: Ingredient names, concentrations, formulation and intended use.
• Label Copy: Statements of indication, warnings, directions for use, and sponsor contact details.
• Manufacturing Records: Facility information, batch records and quality control data.

Submit The Listing And Attestations

Using the TGA’s electronic systems, create the ARTG listing entry and supply the product data. The sponsor attests the information is accurate and the product is eligible for listing. The TGA does not routinely perform pre‑market evaluation of listed products, but it may audit listings or require additional evidence if concerns arise.

Post‑Market Obligations

After listing, the sponsor must maintain records, monitor safety reports and comply with advertising rules. Adverse events should be reported to the TGA according to its guidelines. Keep product information up to date on the ARTG, including changes to formulation, manufacturing site or labelling; some changes may require a new listing or additional TGA notification.

Practical Checklist For Sponsors

• Eligibility Audit: Document why the product qualifies for listing rather than registration.
• eBS Access: Ensure sponsor has active TGA eBusiness Services credentials.
• Complete Data Package: Ingredient list, label copy, manufacturing and quality records.
• Adverse Event Process: Implement a system for receiving and reporting safety information.
• Record Retention: Keep records for the period required by the TGA and be ready for audits.

Tips For International Partners And Retailers

International manufacturers working with Australian sponsors should formalize roles and responsibilities in written agreements. U.S. retailers importing AUST L products must confirm that product labelling and claims comply with the destination market and ensure customs and import documentation are complete. When in doubt, request the ARTG listing number and sponsor contact so you can verify the product directly on the TGA website.

In short, the AUST L Listed Medicine listing process is a documented, sponsor‑led ARTG pathway that requires careful eligibility checks, complete product information, and robust post‑market controls to ensure ongoing compliance for lower‑risk medicines.